As an accessible cell-surface, coordinating receptor on nonCSC tumor cells, CSCs and tumor microvessels involved in key tumor-progression events, DEspR inhibition opens a novel targeted therapy approach for pancreatic cancer and glioblastoma. This evidence concerns the gene FBXW7-AS1 and pancreatic neoplasm.